Nasdaq GlobeNewswire

XBiotech Publishes Results in PLOS ONE for its True Human Antibody 514G3 Targeting S. aureus

Del

Report Documents 514G3's Ability to Protect Mice Against Deadly S. aureus Bacteremia Infections

AUSTIN, Texas, Jan. 25, 2018 (GLOBE NEWSWIRE) -- XBiotech Inc. (NASDAQ:XBIT) announced today the publication of "A Natural Human Monoclonal Antibody Targeting Staphylococcus Protein A Protects Against Staphylococcus aureus (S. aureus) Bacteremia ." in the journal PLOS ONE. The article reports on research involving the Company's therapeutic monoclonal antibody, 514G3, and its ability to neutralize a key immune evasion mechanism of S. aureus involved in the establishment of serious or even deadly infections. The 514G3 antibody was a naturally occurring antibody derived from a healthy individual with highly targeted immunity against S. aureus capable of neutralizing all strains of the bacteria, including a drug-resistant or so-called MRSA form.

"Continued emergence of multi drug resistant strains of S. aureus along with increased aging and immunocompromised populations, contribute to a need for new solutions to this deadly infection," commented Dr. Sushma Shivaswamy, Ph.D., XBiotech's Chief Scientific Officer. She further stated, "The present study confirms the mechanism of action of 514G3, and its ability to neutralize and kill the bacteria in a strain-independent manner."

The Company has previously announced top-line results from a Phase I/II clinical study, which reported a reduction in adverse events and shorter hospitalization associated with the 514G3 therapy, even with 514G3-treated patients tending to be sicker than those receiving placebo. The U.S. FDA has recognized the potential of this treatment, designating this as a Fast Track development program.

About True Human(TM) Therapeutic Antibodies
XBiotech's True Human(TM) antibodies are derived without modification from individuals who possess natural immunity to certain diseases. With discovery and clinical programs across multiple disease areas, XBiotech's True Human antibodies have the potential to harness the body's natural immunity to fight disease with increased safety, efficacy and tolerability.

About XBiotech
XBiotech is a fully integrated global biosciences company dedicated to pioneering the discovery, development and commercialization of therapeutic antibodies based on its True Human(TM) proprietary technology. XBiotech currently is advancing a robust pipeline of antibody therapies to redefine the standards of care in oncology, inflammatory conditions and infectious diseases. Headquartered in Austin, Texas, XBiotech also is leading the development of innovative biotech manufacturing technologies designed to more rapidly, cost-effectively and flexibly produce new therapies urgently needed by patients worldwide. For more information, visit www.xbiotech.com.

Cautionary Note on Forward-Looking Statements
This press release contains forward-looking statements, including declarations regarding management's beliefs and expectations that involve substantial risks and uncertainties. In some cases, you can identify forward-looking statements by terminology such as "may," "will," "should," "would," "could," "expects," "plans," "contemplate," "anticipates," "believes," "estimates," "predicts," "projects," "intend" or "continue" or the negative of such terms or other comparable terminology, although not all forward-looking statements contain these identifying words. Forward-looking statements are subject to inherent risks and uncertainties in predicting future results and conditions that could cause the actual results to differ materially from those projected in these forward-looking statements. These risks and uncertainties are subject to the disclosures set forth in the "Risk Factors" section of certain of our SEC filings. Forward-looking statements are not guarantees of future performance, and our actual results of operations, financial condition and liquidity, and the development of the industry in which we operate, may differ materially from the forward-looking statements contained in this press release. Any forward-looking statements that we make in this press release speak only as of the date of this press release. We assume no obligation to update our forward-looking statements whether as a result of new information, future events or otherwise, after the date of this press release.

Contact
Ashley Otero
aotero@xbiotech.com
512-386-2930



This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: XBiotech, Inc via Globenewswire

Om Nasdaq GlobeNewswire

Nasdaq GlobeNewswire
Nasdaq GlobeNewswire
One Liberty Plaza - 165 Broadway
NY 10006 New York

+1 212 401 8700http://www.nasdaqomx.com

NASDAQ (NASDAQ: NDAQ) is a leading provider of trading, exchange technology, information and public company services across six continents.

Følg saker fra Nasdaq GlobeNewswire

Registrer deg med din epostadresse under for å få de nyeste sakene fra Nasdaq GlobeNewswire på epost fortløpende. Du kan melde deg av når som helst.

Siste saker fra Nasdaq GlobeNewswire

Mitratech’s DataStore Helps Financial Services Clients Across the Globe Meet Regulatory Requirements, Reduce Risk and Improve Efficiency12.11.2018 14:01Pressemelding

Major DataStore Update Includes New Reporting Resulting in Greater Visibility and Informed Decision Making AUSTIN, Texas, Nov. 12, 2018 (GLOBE NEWSWIRE) -- To continue to meet growing risk and compliance demands, Mitratech DataStore Enterprise Content Management (ECM) solution now offers advanced reporting capabilities to help financial services reduce risk and improve efficiency across the enterprise. With this new release, Mitratech customers and partners can leverage advanced reporting capabilities that include: Inventory management Workflow management Audit management Performance management “DataStore continues to expand globally. As the only ECM solution dedicated to financial services, we continue to develop our product to meet the unique needs of our clients,” said Jason Cropper, Mitratech Global Head of Product Marketing - GRC. “Compliance and efficiency are pretty much top of mind across the board, and with the enhanced reporting capabilities this release provides, our clients

Starry Leverages Quantenna’s 8x8 MIMO Capabilities to Bring Ultrafast 5G Fixed Wireless Access to Consumers12.11.2018 14:00Pressemelding

SAN JOSE, Calif., Nov. 12, 2018 (GLOBE NEWSWIRE) -- Quantenna Communications, Inc. (NASDAQ : QTNA) and Starry are joining forces to deliver pioneering gigabit Wi-Fi solutions in millimeter wave bands, leveraging Quantenna’s advanced 8x8 MIMO capabilities and Starry’s smart antenna RF technology. The integration of Quantenna 802.11ac and 802.11ax (Wi-Fi 6) chipsets in Starry’s base station technology, Starry Beam, provides end users with ultrafast speeds, increased bandwidth capacity, reliable connections and extended range. Starry first launched its pre-standard 5G, point-to-multipoint fixed wireless technology in 2016 in Boston; with Quantenna, Starry will continue to expand its network footprint to cities across the country, including Los Angeles, Washington, DC and New York City. Quantenna QSR10GU and QSR10GU-AX solutions support up to 10Gbps speed, 8x8 MIMO and advanced multi-user MIMO, delivering the maximum capacity within the minimum utilized spectrum, resulting in superior perf

Bombardier-Alstom consortium to supply 153 additional AZUR metro cars for Montréal12.11.2018 13:48Pressemelding

Order valued at approximately $448 million CDN With 60% Canadian content, contract will leverage a network of several hundred suppliers across Québec BERLIN, Nov. 12, 2018 (GLOBE NEWSWIRE) -- Note to editors: To view the photo associated with this press release, please visit the following link: http://www.globenewswire.com/NewsRoom/AttachmentNg/a083fc50-492b-4958-8e12-e4f8f1a596d1 The consortium comprising Bombardier Transportation and Alstom has signed an amendment to the initial acquisition contract of October 2010, concluded with Société de transport de Montréal (STM), for the supply of an additional 153 metro cars (17 nine-car trainsets). These cars will move more riders each day with greater reliability and comfort. The value of this new order is approximately $448 million CDN ($340 million US, 299 million euro). Bombardier's share is valued at $281 million CDN ($213 million US, 188 million euro), and Alstom's share is valued at $167 million CDN ($127 million US, 112 million euro)

Standard Lithium Signs Joint Venture Term Sheet With Global Specialty Chemical Company LANXESS12.11.2018 12:30Pressemelding

VANCOUVER, British Columbia, Nov. 12, 2018 (GLOBE NEWSWIRE) -- Standard Lithium Ltd. (“Standard Lithium” or the “Company”) (TSXV: SLL) (OTC-NASDAQ INTL DESIGNATION: STLHF) (FRA: S5L), announces that it has signed a term sheet (the “Term Sheet”) with global specialty chemical company LANXESS Corporation (“LANXESS”) for a contemplated joint venture in the commercial production of battery grade lithium from brine extracted from the Smackover Formation in South Arkansas. Standard Lithium is working with LANXESS in a phased approach as per terms of a binding memorandum of understanding, to develop commercial opportunities related to the production, marketing and sale of battery grade lithium products extracted from brine produced from the Smackover Formation. Under the proposed terms of the joint venture, LANXESS would contribute lithium extraction rights and grant access to its existing infrastructure to the joint venture, and Standard Lithium would contribute existing rights and leases he

Media Alert: Fifteenth World Robot Olympiad Finals Set in Thailand12.11.2018 11:00Pressemelding

Surprise Rules & Automation Will Challenge Young Competitors to Solve Real Problems at Popular Annual Event SUNNYVALE, Calif. and BILLUND, Denmark, Nov. 12, 2018 (GLOBE NEWSWIRE) -- The World Robot Olympiad™ Association plus joint sponsors LEGO® Education and Juniper Networks (NYSE: JNPR), an industry leader in automated, scalable and secure networks, today announced this year’s global finals are due to take place starting this Friday, November 16, in Chiang Mai, Thailand. Four-hundred and eighty-four teams, comprising over 1,200 individuals from 63 different countries, are due to participate across eight age- and task-based categories. The teams will demonstrate their ability to problem-solve and innovate using LEGO-based robots they have designed, built and programmed themselves. This year’s event has a theme of ‘Food Matters’, around which some of the competitive challenges are based. The challenges are known in advance so the teams can prepare their approach, but they must also dea

Mash Group Plc Reports Interim Unaudited Q3 Financials, ended 30th September 201812.11.2018 10:17Pressemelding

Record revenue for the first nine months of 2018, up 167% from Q1-Q3/17. EBIT grew by 186% to EUR 9.5 million and lending volume grew by 161% for the same period. Revenue growing faster than lending volumes in the third quarter and strong growth expected to continue in Q4 2018, according to CEO Hickson. The first nine months of 2018 showed record growth in revenue, EBIT, lending volume and loan book as Mash continues to execute its growth plan. Strategic Highlights Mash announces launch of EUR 50 million equity issue as well as Europe’s first regulated digital share issue. Mash pay later services were launched in Sweden with partner Verifone. Mash develops partnership with Nets for ecommerce and point of sale, a leading payment services operator in the Nordic market. Operational Highlights The number of new customers grew by 229% Q1-Q3/18 compared to Q1-Q3/17. Registered merchants for Mash’s pay later point of sale solution grew 1054% year to date. The Mash Net Promoter Score reached 8

I vårt presserom finner du alle våre siste saker, kontaktpersoner, bilder, dokumenter og annen relevant informasjon om oss.

Besøk vårt presserom